5PSQ-074 Activity of enzalutamide after abiraterone in castration-resistant prostate cancer

BACKGROUND: There is only limited information about the sequential use of abiraterone acetate (AA) and enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC) patients. Patients who receive AA or ENZ as first-line therapy and subsequently become resistant have only a response r...

詳細記述

保存先:
書誌詳細
出版年:Eur J Hosp Pharm
主要な著者: Soto, A Alcalá, Moreno, R Gavira, Sánchez, JF Sierra, Pérez, A Varas, Pichardo, L Jiménez, Moreno, C Puivecino, Calvo, MT Gómez de Travecedo y
フォーマット: Artigo
言語:Inglês
出版事項: BMJ Group 2018
主題:
Section 5: Patient safety and quality assurance
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535372/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.428
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料